Transaction · 0000914190-26-000133
TECHBIO-TECHNE Corp
Kelderman Kim
Kelderman Kim, CEO, reported a transaction classified as grant at BIO-TECHNE Corp involving 57590.000000 shares for an estimated $0.00. Reported holdings after the transaction were 57590.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
grantSEC transaction code ACEO
- Trade date
- Aug 17, 2026
- Filing date
- Aug 19, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TECH price since this filing
Daily closing prices, with the filing date and available return windowsTECH · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.5%1w ago -0.5%1d ago -0.1%
Returns since7d -0.1%30d -0.1%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0000914190-26-000133 Restricted Stock Units
- Transaction date
- Aug 17, 2026 Filed Aug 19, 2026, 08:48 PM · 2d delay
- Shares
- 57,590 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 57,590 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
Mixed or weak signal
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Executive Officer
Officer YesDirector Yes10% NoOther No
Footnotes & amended
- F1
Fully exercisable.
- F2
Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
- F3
Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
- F4
Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
- F5
Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
- F6
Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F7
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F8
Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9
Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F10
8,544 restricted stock units vest on 8/15/2027.
- F11
11,785 restricted stock units vest on 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
- F12
19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
- F13
93,582 restricted stock units vest on 8/17/2029.
Related transactions
Same SEC filing0 other transactions
Recent company activity
TECH0 recent txs